Cocrystal Pharma, Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

COCP$1.11+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(Dollars and shares in thousands, except per share data)

	December 31, 2025	December 31, 2024
Assets
Current assets:
Cash	$7,025	$9,860
Restricted cash	75	75
Tax credit receivable	706	1,215
Prepaid expenses and other current assets	328	430
Total current assets	8,134	11,580
Property and equipment, net	93	153
Deposits	95	29
Operating lease right-of-use assets, net (including $152 and $42 to related party)	1,390	1,694
Total assets	$9,712	$13,456
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$1,876	$2,127
Current maturities of operating lease liabilities (including $49 and $42 to related party)	334	301
Total current liabilities	2,210	2,428
Long-term liabilities:
Operating lease liabilities (including $104 and $0 to related party)	1,171	1,505
Total long-term liabilities	1,171	1,505
Total liabilities	3,381	3,933
Commitments and contingencies	-	-
Stockholders’ equity:
Common stock $0.001 par value; 100,000 and 150,000 shares authorized as of December 31, 2025 and 2024, respectively; 13,784 and 10,174 shares issued and outstanding as of December 31, 2025 and 2024, respectively	13	10
Additional paid-in capital	348,567	342,931
Accumulated deficit	(342,249)	(333,418)
Total stockholders’ equity	6,331	9,523
Total liabilities and stockholders’ equity	$9,712	$13,456

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.